samedan logo
home > news > detailed info

AstraZeneca Expands Role in Rare Disease by Acquiring Alexion Pharmaceuticals


Today marks the beginning of Alexion’s next chapter, with the exciting news that we have been acquired by AstraZeneca, a global, science-led biopharmaceutical company. This development also marks the creation of Alexion, AstraZeneca Rare Disease.

Alexion and AstraZeneca share a dedication to science, to innovation, and to delivering life-changing medicines to the patients who need them most. Together, we have the opportunity to add more value for more patients worldwide across a full-spectrum of care.

Alexion’s innovative complement-biology platforms and robust pipeline place AstraZeneca in a strong position for enhancing its scientific presence in the immunology sector. Most importantly, together we will be better positioned to ensure the ongoing discovery and development of medicines for rare diseases and devastating conditions.

Pascal Soriot, Chief Executive Officer of AstraZeneca, said: “Today we welcome our new colleagues from Alexion to AstraZeneca and begin a new chapter that will augment our growth for years to come. Our sustained R&D investment in oncology, cardiovascular and renal, as well as respiratory and immunology, has powered AstraZeneca’s transformation and now we add rare diseases, where fewer approved treatment options exist.”

Marc Dunoyer, incoming Chief Executive Officer of Alexion and Chief Financial Officer, AstraZeneca said: “I am delighted to be working alongside my new colleagues at Alexion where we will continue to discover, develop and deliver medicines that change the lives of people suffering from rare diseases. We look forward to also applying Alexion’s complement-biology platform across areas of AstraZeneca’s broader early stage pipeline and, significantly, to the extraordinary opportunity to extend existing and future rare disease medicines to patients in many countries where AstraZeneca already has a strong presence.”
phone 0207 604 8000
Print this page
Send to a friend
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement